Volume : 13, Issue : 04, April – 2026

Title:

A CLINICAL EVALUATION OF TRYPACE VERSUS ACTON OR: PAIN REDUCTION, RECOVERY TIME, AND ADVERSE DRUG REACTIONS

Authors :

T. Rajitha Sree*, Sujit Kumar V, P Jessica, Nasu Priyadarshini, Najam Uddin Siddiqui1, Bilal Ahmed, Chandra Sekhara Rao Baru

Abstract :

Pain is a complex Sensory and inflammatory response that significantly impact individuals quality of life and functional capacity. The goal of this prospective observational study was to see how Acton OR and Trypace worked in a teaching hospital for tertiary care. There were 350 people in the trial and they were all between the ages of 19 to 60. There were 175 people in each group, Group A (Trypace) and Group B (Acton OR). We also looked at how long it took each group to get better. The data demonstrated a statistically significant reduction in the mean pain scores for both groups overtime(p<0.001). At the start , the Trypace group’s average pain score was 6.96. At follow-up 1, it was 4.09, and at follow-up 2, it was 1.58. The Acton OR group’s average pain scores dropped from 6.86 at the start to 4.92 at follow-up 1 and 3.02 at follow-up 2. Trypace on the other hand, showed a bigger drop in pain intensity, which means it works better. Medication adherence was high in both groups (98.9% for Trypace and 96.6% for Acton OR), with no statistically significant difference. While both medications relieved pain, Trypace was more effective with shorter recovery time, whereas Actor OR was safer and had no reported adverse reactions. Thus, Acton OR may be optimal for safety focused patients, whereas Trypace suits those needing immediate relief. Further randomised controlled trials are recommended to validate these findings.
Keywords: Pain management, analgesics, anti-inflammatory drugs, medication adherence, adverse drug reactions, Visual analogue scale, Recovery time.

Cite This Article: